OTLC Oncotelic Therapeutics, Inc.

OTC Pharmaceutical Preparations DE CIK: 0000908259
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

Oncotelic faces severe financial distress with revenue collapsed 96% YoY to $70K, operating losses of $658K, and critically low liquidity (0.08x current ratio) on only $409K cash. With negative operating cash flow of $600K annually, the company has less than one year of cash runway, posing significant going concern risk.

Strengths

  • + Slight improvement in net loss magnitude YoY (minor positive momentum in loss trajectory)
  • + Debt-to-equity ratio of 0.14x is not highly leveraged
  • + Retains $28.2M in total assets providing some buffer

Risks

  • ! Revenue collapsed 96% YoY indicating loss of commercial viability and market acceptance
  • ! Critically low liquidity (0.08x current ratio) indicating imminent cash crisis and inability to meet short-term obligations
  • ! Negative $613K free cash flow with only $409K cash remaining suggests sub-one-year runway before insolvency
  • ! Deeply negative operating margins (-940%) and net margins (-1526%) with no clear profitability path
  • ! Potential going concern failure requiring debt restructuring or capital infusion
  • ! Minimal insider activity (1 Form 4 filing in 90 days) suggests lack of management confidence

Key Metrics to Watch

Financial Metrics

Revenue
70.0K
Net Income
-1.1M
EPS (Diluted)
$0.00
Free Cash Flow
-613.1K
Total Assets
28.2M
Cash
409.0K

Profitability Ratios

Gross Margin N/A
Operating Margin -940.1%
Net Margin -1,526.0%
ROE -11.8%
ROA -3.8%
FCF Margin -875.9%

Balance Sheet & Liquidity

Current Ratio
0.08x
Quick Ratio
0.08x
Debt/Equity
0.14x
Debt/Assets
71.3%
Interest Coverage
-2.80x
Long-term Debt
1.3M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-04-14T21:12:22.770450 | Data as of: 2025-09-30 | Powered by Claude AI